ClinicalTrials.gg
CompletedNCT00105287Updated May 9, 2014

Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

A Phase 3 interventional study of OraVescent fentanyl (OVF) in Pain and Cancer, sponsored by Cephalon. Completed at 26 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-05-09.

Sponsored by Cephalon (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Pain by Teva Pharmaceutical Industries, Ltd. — none open to participants now, none under way, none of them phase 3. Pain · Teva Pharmaceutical Industries, Ltd..

Started
2005
with 1 other
Phase 3
6 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Pain by Teva Pharmaceutical Industries, Ltd., this one is one of 2 that started in 2005, is one of 6 in phase 3, and was the 1st registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 11 studies in Pain by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Pain by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.

03

Conditions studied

  • Pain
  • Cancer

Keywords

  • cancer
  • pain
  • Breakthrough Pain in cancer patients
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of a malignant solid tumor or hematological causing cancer related pain
  • Currently taking around the clock opioid therapy for pain
  • Experience on average, 1-4 breakthrough pain episodes per day

Exclusion criteria

Exclusion Criteria:

  • Opioid or fentanyl intolerance
  • Sleep apnea or active with increased intracranial pressure
  • (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants

Interventions

  • DrugOraVescent fentanyl (OVF)
06

Study locations

26 sites
  • Cullman Oncology and Hematology
    Cullman, Alabama 35058, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Pacific Cancer Medical Center
    Anaheim, California 92801, United States
  • Compassionate Cancer Care Medical Group
    Corona, California 92882, United States
  • Compassionate Cancer Center
    Fountain Valley, California 92708, United States
  • Clinical Trials & Research Associates, Inc.
    Montebello, California 90640, United States
  • San Diego Hospice & Palliative Care
    San Diego, California 92103, United States
  • Pacific Clinical Research
    Santa Monica, California 90404, United States
  • Lovelace Scientific Resources
    Miami, Florida 33143, United States
  • Gulf Coast Pain Specialists
    Pensacola, Florida 32503, United States
  • Hematology Oncology Associates of Treasure Coast
    Port St. Lucie, Florida 34952, United States
  • Center for Prospective Outcome
    Marietta, Georgia 30060, United States
  • Iowa Pain Management Clinic, PC
    Des Moines, Iowa 50265, United States
  • Donald Berdeaux
    Great Falls, Montana 59405, United States
  • Great Falls Clinic, LLP
    Great Falls, Montana 59405, United States
  • Southern Nevada Cancer Research
    Las Vegas, Nevada 89106, United States
  • NYU Pain Management Center
    New York, New York 10016, United States
  • Research Across America
    New York, New York 10021, United States
  • Brody School of Medicine
    Greenville, North Carolina 27858, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Charleston Hematology Oncology, PA
    Charleston, South Carolina 29403, United States
  • University of Rochester
    San Antonio, Texas 78229, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • Cache Valley Cancer Treatment and Research Clinic, Inc.
    West Point, Utah 84015, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Sep 2006 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2005
First posted
Mar 14, 2005
Start
Jan 2005
Primary completionActual
Sep 2006
CompletionActual
Sep 2007
Last update
May 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00105287
Lead sponsor
Cephalon
Responsible party
Sponsor
First posted
Mar 14, 2005
Start date
Jan 2005
Primary completion
Sep 2006
Completion
Sep 2007
Last update
May 9, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion